AXL regulates mesothelioma proliferation and invasiveness
W-B Ou1, J M Corson, D L Flynn
1Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Mesothelioma is an asbestos-associated and notoriously chemotherapy-resistant neoplasm. Activation of the receptor tyrosine kinases (RTKs), epidermal growth factor receptor and MET, has been described in subsets of mesothelioma, suggesting that TKs might represent therapeutic targets in this highly lethal disease. We employed proteomic screening by phosphotyrosine immunoaffinity purification and tandem mass spectrometry to characterize RTK activation in mesothelioma cell lines. These assays demonstrated expression and activation of the AXL protein, which is an RTK with known oncogenic properties in non-mesothelial cancer types. AXL was expressed and activated strongly in 8 of 9 mesothelioma cell lines and 6 of 12 mesothelioma biopsies, including each of 12 mesotheliomas with spindle-cell histology. Somatic AXL mutations were not found, but all mesotheliomas expressed an alternatively spliced AXL transcript with in-frame deletion of exon 10, and six of seven mesothelioma cell lines expressed the AXL ligand, growth arrest-specific 6 (GAS6). GAS6 expression appeared to be functionally relevant, as indicated by modulation of AXL tyrosine phosphorylation by knockdown of endogeneous GAS6, and by administration of exogenous GAS6. AXL silencing by lentivirus-mediated short hairpin RNA suppressed mesothelioma migration and cellular proliferation due to G1 arrest. The AXL inhibitor DP-3975 inhibited cell migration and proliferation in mesotheliomas with strong AXL activation. DP-3975 response in these tumors was characterized by inhibition of PI3-K/AKT/mTOR and RAF/MAPK signaling. AXL inhibition suppressed mesothelioma anchorage-independent growth, with reduction in colony numbers and size. These studies suggest that AXL inhibitors warrant clinical evaluation in mesothelioma.
Insights
AXL receptor tyrosine kinase (RTK) is activated in mesothelioma, a chemotherapy-resistant cancer. Inhibiting AXL suppressed mesothelioma growth and migration, suggesting AXL inhibitors as potential mesothelioma therapeutics.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Mesothelioma is a rare, asbestos-associated cancer known for its resistance to chemotherapy.
- Receptor tyrosine kinases (RTKs) like EGFR and MET are implicated in mesothelioma, suggesting their potential as therapeutic targets.
- AXL, an RTK with oncogenic roles in other cancers, was investigated for its role in mesothelioma.
Purpose of the Study:
- To investigate the expression and activation of AXL receptor tyrosine kinase (RTK) in mesothelioma.
- To determine the functional relevance of AXL and its ligand GAS6 in mesothelioma cell lines.
- To evaluate the therapeutic potential of AXL inhibition in mesothelioma.
Main Methods:
- Proteomic screening using phosphotyrosine immunoaffinity purification and tandem mass spectrometry.
- Analysis of AXL expression and activation in mesothelioma cell lines and patient biopsies.
- Functional studies involving AXL knockdown, GAS6 modulation, and treatment with the AXL inhibitor DP-3975.
Main Results:
- AXL was highly expressed and activated in 8/9 mesothelioma cell lines and 6/12 mesothelioma biopsies, particularly those with spindle-cell histology.
- An alternatively spliced AXL transcript lacking exon 10 was found in all mesotheliomas.
- AXL inhibition by DP-3975 suppressed mesothelioma cell migration, proliferation, and anchorage-independent growth by affecting PI3-K/AKT/mTOR and RAF/MAPK signaling pathways.
Conclusions:
- AXL is a frequently activated RTK in mesothelioma and plays a significant role in tumor growth and migration.
- AXL signaling pathways are critical for mesothelioma cell proliferation and survival.
- AXL inhibitors, such as DP-3975, show promise as a targeted therapy for mesothelioma and warrant clinical evaluation.
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
The Intrinsic Apoptotic Pathway

